Division of Infectious Diseases

ID Journal Club Presents…Antimicrobial Stewardship in Immunocompromised Patients with Febrile Neutropenia of Unknown Origin– Focusing on Early De-escalation

Targeted therapy and antimicrobial stewardship in patients with febrile neutropenia is difficult because in the vast majority of cases, an organism is not identified, and patients are known to be high risk for serious infections. Antibiotic de-escalation in patients with neutropenic fever varies, with European guidelines recommending 72hr de-escalation and North American guidelines recommending continuation of broad spectrum therapy until neutrophil engraftment. Dr. Jasmine Marcelin… Continue Reading

UNMC ID Welcomes New M1 Enhanced Medical Education Track Students

The UNMC College of Medicine offers a unique Enhanced Medical Education Track (EMET) program which provides an opportunity for medical students to delve into particular disciplines of interest in the field of medicine throughout their four year degree program. Track students attend seminars, preceptorships and complete a research project culminating in a poster or conference presentation. More information about the EMET program can be found here…. Continue Reading

Ryan Ross, RN on Why I Love ID

Why I Love ID: “Why I love ID? I love ID because it brought me many new challenges as a nurse. I’ve been able to learn in depth about infections ranging from Tuberculosis to prosthetic joint infections. I love being part of a team that has the knowledge and expertise to be able to diagnose infections that others could not find. It’s very rewarding to… Continue Reading

Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Biktarvy, a new co-formulated integrase inhibitor-based treatment approved for HIV On February 7th 2018, the Food and Drug Administration approved a new combination antiretroviral drug called Biktarvy®(1). Biktarvy® (B/F/TAF) is a single-tablet, once daily regimen containing the novel integrase strand transfer inhibitor bictegravir coformulated with emtricitabine and tenofovir alafenamide (1). Current HIV guidelines recommend integrase strand transfer inhibitor… Continue Reading